DRMAHealthcare · BiotechnologyDRMA Stock Forecast: Dermata Therapeutics, Inc. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Dermata Therapeutics, Inc. hold a median 12-month price target of $4 — +272.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
DRMA stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Dermata Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (96): Smaller than most of the companies we track.
Quality (6): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own Dermata Therapeutics, Inc. — and when they’d sell — is the membership.
DRMA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on DRMA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +272.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 Aug 2025 | Maxim Group | Maintains | Buy | $30 → $10 |
| 21 May 2025 | Maxim Group | Maintains | Buy | — |
| 21 Aug 2024 | Maxim Group | Maintains | Buy | — |
| 23 Mar 2023 | Maxim Group | Maintains | Buy | — |
| 21 Sept 2021 | Brookline Capital | Initiates | Buy | $14 |
| 14 Sept 2021 | Maxim Group | Initiates | Buy | $9.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
DRMA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Dermata Therapeutics, Inc. (DRMA) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.1×
- Price / sales
- —
- Price / book
- 0.7×
- EV / EBITDA
- 0.3×
Cheaper than 72% of US stocks
Cheaper than 79% of US stocks
Cheaper than 60% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −103.6%
- Return on assets
- −52.7%
- Dividend yield
- —
Higher than 12% of US stocks
Higher than 7% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
DRMA vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DRMA appears on the weeks it earns a place.
Frequently asked questions about DRMA stock
What is the DRMA stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Dermata Therapeutics, Inc. have a median 12-month price target of $4, with estimates ranging from $4 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is DRMA stock a buy right now?
Of the 1 analysts covering Dermata Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Dermata Therapeutics, Inc. 21 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank DRMA?
As at 1 Aug 2026, Dermata Therapeutics, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).
Will DRMA stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +272.1% from the last close, and Ticker Nerd's factor model ranks Dermata Therapeutics, Inc. 21 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the DRMA stock forecast for 2030?
No analyst covering Dermata Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DRMA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.
How has DRMA stock performed over the past year?
Dermata Therapeutics, Inc. returned -83.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Dermata Therapeutics, Inc. do?
Dermata Therapeutics Inc. is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for medical skin diseases and aesthetic applications.
About Dermata Therapeutics, Inc.
Dermata Therapeutics Inc. is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for medical skin diseases and aesthetic applications. Its lead product candidate, XYNGARI, is in Phase 3 clinical studies for moderate-to-severe acne and has completed Phase 1b proof-of-concept trials for mild-to-moderate psoriasis. The company is also advancing DMT410, which has completed Phase 1b proof-of-concept trials for axillary hyperhidrosis and aesthetic skin conditions, utilizing its proprietary Spongilla technology platform for intradermal delivery, including topical botulinum toxin. Dermata Therapeutics Inc. leverages this technology across dermatologic treatments for conditions like acne, psoriasis, rosacea, and seborrheic dermatitis, aiming to deliver innovative once-weekly topical therapies. It maintains clinical trial collaborations to evaluate combinations such as XYNGARI with botulinum toxin products. Founded in 2014 and headquartered in San Diego, California, Dermata Therapeutics Inc. plays a key role in advancing targeted dermatology solutions in the biotechnology sector.
CEO Mr. Gerald T. Proehl · 9 employees · United States · https://www.dermatarx.com